Antithrombotic therapy for left ventricular assist devices in adults: A systematic review

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 6, 2015, Pages 946-955

  Baumann Kreuziger, L M ^a   Kim, B ^b   Wieselthaler, G M ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulants; Hemorrhage; Platelet aggregation inhibitors; Thrombosis; Ventricular assist device

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; CLOPIDOGREL; DIPYRIDAMOLE; HEPARIN; HIRULOG; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DEVICE FAILURE; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; HEART RIGHT VENTRICLE FAILURE; HUMAN; INFECTION; INTERNATIONAL NORMALIZED RATIO; LEFT VENTRICULAR ASSIST DEVICE; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RISK; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; ADVERSE EFFECTS; BLEEDING; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; DRUG EFFECTS; DRUG MONITORING; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; ODDS RATIO; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ANTICOAGULANTS; BLOOD COAGULATION; CHI-SQUARE DISTRIBUTION; DRUG MONITORING; FIBRINOLYTIC AGENTS; HEART FAILURE; HEART-ASSIST DEVICES; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; ODDS RATIO; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PROSTHESIS DESIGN; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84930181665     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12948     Document Type: Article

References (54)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-215.
2. Fang JC. Rise of the machines-left ventricular assist devices as permanent therapy for advanced heart failure. N Engl J Med 2009; 361: 2282-5.
3. Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, Dobbels F, Goldfarb SB, Levvey BJ, Meiser B, Yusen RD, Stehlik J. The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Official Adult Heart Transplant Report-2014; Focus Theme: Retransplantation. J Heart Lung Transplant 2014; 33: 996-1008.
4. Johnson MR, Meyer KH, Haft J, Kinder D, Webber SA, Dyke DB. Heart transplantation in the United States, 1999-2008. Am J Transplant 2010; 10: 1035-46.
5. Miller LW, Guglin M. Patient selection for ventricular assist devices: a moving target. J Am Coll Cardiol 2013; 61: 1209-21.
6. Martin J, Friesewinkel O, Benk C, Sorg S, Schultz S, Beyersdorf F. Improved durability of the HeartMate XVE left ventricular assist device provides safe mechanical support up to 1 year but is associated with high risk of device failure in the second year. J Heart Lung Transplant 2006; 25: 384-90.
7. Chiu WC, Girdhar G, Xenos M, Alemu Y, Soares JS, Einav S, Slepian M, Bluestein D. Thromboresistance comparison of the HeartMate II ventricular assist device with the device thrombogenicity emulation- optimized HeartAssist 5 VAD. J Biomech Eng 2014; 136: 021014.
8. Birschmann I, Dittrich M, Eller T, Wiegmann B, Reininger AJ, Budde U, Struber M. Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices. J Heart Lung Transplant 2014; 33: 80-7.
9. Jarvik R. Jarvik 2000 pump technology and miniaturization. Heart Fail Clin 2014; 10: S27-38.
10. Esmore D, Spratt P, Larbalestier R, Tsui S, Fiane A, Ruygrok P, Meyers D, Woodard J. VentrAssist left ventricular assist device: clinical trial results and Clinical Development Plan update. Eur J Cardiothorac Surg 2007; 32: 735-44.
11. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM 3rd, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241-51.
12. Jorde UP, Kushwaha SS, Tatooles AJ, Naka Y, Bhat G, Long JW, Horstmanshof DA, Kormos RL, Teuteberg JJ, Slaughter MS, Birks EJ, Farrar DJ, Park SJ. Results of the destination therapy post-food and drug administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2014; 63: 1751-7.
13. Eckman PM, John R. Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. Circulation 2012; 125: 3038-47.
14. Goldstein DJ, John R, Salerno C, Silvestry S, Moazami N, Horstmanshof D, Adamson R, Boyle A, Zucker M, Rogers J, Russell S, Long J, Pagani F, Jorde U. Algorithm for the diagnosis and management of suspected pump thrombus. J Heart Lung Transplant 2013; 32: 667-70.
15. Bunte MC, Blackstone EH, Thuita L, Fowler J, Joseph L, Ozaki A, Starling RC, Smedira NG, Mountis MM. Major bleeding during heartmate II support. J Am Coll Cardiol 2013; 62: 2188-96.
16. Crow S, Chen D, Milano C, Thomas W, Joyce L, Piacentino V 3rd, Sharma R, Wu J, Arepally G, Bowles D, Rogers J, Villamizar-Ortiz N. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg 2010; 90: 1263-9; discussion 9.
17. Meyer AL, Malehsa D, Bara C, Budde U, Slaughter MS, Haverich A, Strueber M. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail 2010; 3: 675-81.
18. Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW, Deng M, Dickstein ML, El-Banayosy A, Elliot T, Goldstein DJ, Grady KL, Jones K, Hryniewicz K, John R, Kaan A, et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 2013; 32: 157-87.
19. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008.
20. Bishop MA, Streiff MB, Ensor CR, Tedford RJ, Russell SD, Ross PA. Pharmacist-managed international normalized ratio patient self-testing is associated with increased time in therapeutic range in patients with left ventricular assist devices at an academic medical center. ASAIO J 2014; 60: 193-8.
21. Demirozu ZT, Radovancevic R, Hochman LF, Gregoric ID, Letsou GV, Kar B, Bogaev RC, Frazier OH. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant 2011; 30: 849-53.
22. Hayes HM, Dembo LG, Larbalestier R, O'Driscoll G. Management options to treat gastrointestinal bleeding in patients supported on rotary left ventricular assist devices: a single-center experience. Artif Organs 2010; 34: 703-6.
23. Jennings D, McDonnell J, Schillig J. Assessment of long-term anticoagulation in patients with a continuous-flow left-ventricular assist device: a pilot study. J Thorac Cardiovasc Surg 2011; 142: e1-2.
24. Karimi A, Beaver TM, Hess PJ, Martin TD, Staples ED, Schofield RS, Hill JA, Aranda JM, Klodell CT. Close antiplatelet therapy monitoring and adjustment based upon thrombelastography may reduce late-onset bleeding in HeartMate II ecipients. Interact Cardiovasc Thorac Surg 2014; 18: 457-65.
25. Litzler PY, Smail H, Barbay V, Nafeh-Bizet C, Bouchart F, Baste JM, Abriou C, Bessou JP. Is anti-platelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience Eur J Cardiothorac Surg 2014; 45: 55-9; discussion 9-60.
26. Menon AK, Gotzenich A, Sassmannshausen H, Haushofer M, Autschbach R, Spillner JW. Low stroke rate and few thrombo-embolic events after HeartMate II implantation under mild anticoagulation. Eur J Cardiothorac Surg 2012; 42: 319-23; discussion 23.
27. Meyer AL, Malehsa D, Budde U, Bara C, Haverich A, Strueber M. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail 2014; 2: 141-5.
28. Morgan JA, Paone G, Nemeh HW, Henry SE, Patel R, Vavra J, Williams CT, Lanfear DE, Tita C, Brewer RJ. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. J Heart Lung Transplant 2012; 31: 715-8.
29. Muthiah K, Robson D, Macdonald PS, Keogh AM, Kotlyar E, Granger E, Dhital K, Spratt P, Hayward CS. Increased incidence of angiodysplasia of the gastrointestinal tract and bleeding in patients with continuous flow left ventricular assist devices (LVADs). Int J Artif Organs 2013; 36: 449-54.
30. Pieri M, Agracheva N, Di Prima AL, Nisi T, De Bonis M, Isella F, Zangrillo A, Pappalardo F. Primary anticoagulation with bivalirudin for patients with implantable ventricular assist devices. Artif Organs 2014; 38: 342-6.
31. Stern DR, Kazam J, Edwards P, Maybaum S, Bello RA, D'Alessandro DA, Goldstein DJ. Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD. J Card Surg 2010; 25: 352-6.
32. von Potapov E, Stepanenko A, Kaufmann F, Henning E, Vierecke J, Lehmkuhl E, Hetzer R, Krabatsch T. Thrombosis and cable damage in the HeartWare Pump: clinical decisions and surgical technique. ASAIO J 2013; 59: 37-40.
33. Whitson BA, Eckman P, Kamdar F, Lacey A, Shumway SJ, Liao KK, John R. Hemolysis, pump thrombus, and neurologic events in continuous-flow left ventricular assist device recipients. Ann Thorac Surg 2014; 97: 2097-103.
34. Frazier OH, Gemmato C, Myers TJ, Gregoric ID, Radovancevic B, Loyalka P, Kar B. Initial clinical experience with the HeartMate II axial-flow left ventricular assist device. Tex Heart Inst J 2007; 34: 275-81.
35. Majeed F, Kop WJ, Poston RS, Kallam S, Mehra MR. Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices. Nat Clin Pract Cardiovasc Med 2009; 6: 147-57.
36. Morshuis M, El-Banayosy A, Arusoglu L, Koerfer R, Hetzer R, Wieselthaler G, Pavie A, Nojiri C. European experience of DuraHeart magnetically levitated centrifugal left ventricular assist system. Eur J Cardiothorac Surg 2009; 35: 1020-7; discussion 7-8.
37. Siegenthaler MP, Westaby S, Frazier OH, Martin J, Banning A, Robson D, Pepper J, Poole-Wilson P, Beyersdorf F. Advanced heart failure: feasibility study of long-term continuous axial flow pump support. Eur Heart J 2005; 26: 1031-8.
38. Slaughter MS, Pagani FD, McGee EC, Birks EJ, Cotts WG, Gregoric I, Howard Frazier O, Icenogle T, Najjar SS, Boyce SW, Acker MA, John R, Hathaway DR, Najarian KB, Aaronson KD. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant 2013; 32: 675-83.
39. Moazami N, Steffen RJ, Naka Y, Jorde U, Bailey S, Murali S, Camacho MT, Zucker M, Marascalco PJ, Rao V, Feldman D. Lessons learned from the first fully magnetically levitated centrifugal LVAD trial in the United States: the DuraHeart trial. Ann Thorac Surg 2014; 98: 541-7.
40. Wieselthaler GM, O'Driscoll G, Jansz P, Khaghani A, Strueber M. Initial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multi-institutional trial. J Heart Lung Transplant 2010; 29: 1218-25.
41. Sandner SE, Riebandt J, Haberl T, Mahr S, Rajek A, Schima H, Wieselthaler GM, Laufer G, Zimpfer D. Low-molecular-weight heparin for anti-coagulation after left ventricular assist device implantation. J Heart Lung Transplant 2014; 33: 88-93.
42. Boyle AJ, Jorde UP, Sun B, Park SJ, Milano CA, Frazier OH, Sundareswaran KS, Farrar DJ, Russell SD, HeartMate IICI. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support. J Am Coll Cardiol 2014; 63: 880-8.
43. Stewart GC, Stevenson LW. Keeping left ventricular assist device acceleration on track. Circulation 2011; 123: 1559-68; discussion 68.
44. Almond CS, Buchholz H, Massicotte P, Ichord R, Rosenthal DN, Uzark K, Jaquiss RD, Kroslowitz R, Kepler MB, Lobbestael A, Bellinger D, Blume ED, Fraser CD Jr, Bartlett RH, Thiagarajan R, Jenkins K. Berlin Heart EXCOR Pediatric ventricular assist device Investigational Device Exemption study: study design and rationale. Am Heart J 2011; 162: 425-35 e6.
45. Chitlur M, Sorensen B, Rivard GE, Young G, Ingerslev J, Othman M, Nugent D, Kenet G, Escobar M, Lusher J. Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia 2011; 17: 532-7.
46. Najjar SS, Slaughter MS, Pagani FD, Starling RC, McGee EC, Eckman P, Tatooles AJ, Moazami N, Kormos RL, Hathaway DR, Najarian KB, Bhat G, Aaronson KD, Boyce SW. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant 2014; 33: 23-34.
47. Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, Rame JE, Acker MA, Blackstone EH, Ehrlinger J, Thuita L, Mountis MM, Soltesz EG, Lytle BW, Smedira NG. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 2014; 370: 33-40.
48. Kirklin JK, Naftel DC, Kormos RL, Pagani FD, Myers SL, Stevenson LW, Acker MA, Goldstein DL, Silvestry SC, Milano CA, Timothy Baldwin J, Pinney S, Eduardo Rame J, Miller MA. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. J Heart Lung Transplant 2014; 33: 12-22.
49. Frazier OH. Increase in left ventricular assist device thrombosis. N Engl J Med 2014; 370: 1464-5.
50. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
51. Harper P, Pollock D. Improved anticoagulant control in patients using home international normalized ratio testing and decision support provided through the Internet. Intern Med J 2011; 41: 332-7.
52. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-83.
53. Ballew CC, Benton EM, Groves DS, Kennedy JLW, Ailawaid G, Kern JA, Bergin JD. Comparing survival of HMII patients with elevated LDH: implications for medical and surgical management. J Heart Lung Transplant 2013; 32: S38.
54. Jennings DL, Weeks PA. Thrombosis in continuous-flow left ventricular assist devices: pathophysiology, prevention, and pharmacologic management. Pharmacotherapy 2015; 35: 79-98.